CVN058 Effect on Mismatch Negativity in Schizophrenics
Status:
Completed
Trial end date:
2020-03-06
Target enrollment:
Participant gender:
Summary
This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate
CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN)
downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.